CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Corvus Pharmaceuticals, Inc. - CRVS CFD

8.1284
1.21%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0432
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024124 %
Charges from full value of position ($-4.58)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024124%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001901 %
Charges from full value of position ($0.36)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.001901%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 8.2384
Open 8.1784
1-Year Change 409.65%
Day's Range 7.9484 - 8.1784
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 2, 2024 8.2384 -0.7700 -8.55% 9.0084 9.1284 8.1584
Nov 29, 2024 9.0684 -0.3800 -4.02% 9.4484 9.5084 9.0684
Nov 27, 2024 9.3884 0.6800 7.81% 8.7084 9.4584 8.5884
Nov 26, 2024 8.7184 -0.2200 -2.46% 8.9384 9.2084 8.5884
Nov 25, 2024 8.9184 -0.0700 -0.78% 8.9884 9.3184 8.8584
Nov 22, 2024 8.9284 -0.0100 -0.11% 8.9384 9.1684 8.7084
Nov 21, 2024 8.9184 0.8700 10.81% 8.0484 9.0384 7.9984
Nov 20, 2024 8.2284 -0.0600 -0.72% 8.2884 8.2984 7.9984
Nov 19, 2024 8.3684 0.2200 2.70% 8.1484 8.5684 8.1284
Nov 18, 2024 8.3284 0.0900 1.09% 8.2384 8.6784 8.1484
Nov 15, 2024 8.1684 -0.1200 -1.45% 8.2884 8.4484 7.7584
Nov 14, 2024 8.4984 -0.3900 -4.39% 8.8884 8.8984 7.8684
Nov 13, 2024 8.8484 -0.6400 -6.75% 9.4884 9.9484 8.7684
Nov 12, 2024 8.6684 -0.7000 -7.47% 9.3684 9.6884 8.6484
Nov 11, 2024 9.5184 -0.1000 -1.04% 9.6184 9.8484 9.2684
Nov 8, 2024 9.4584 0.7700 8.86% 8.6884 9.5784 8.6084
Nov 7, 2024 8.7684 0.2700 3.18% 8.4984 9.0684 8.4184
Nov 6, 2024 8.7284 -0.7900 -8.30% 9.5184 9.5984 8.4884
Nov 5, 2024 9.1984 0.3200 3.60% 8.8784 9.3884 8.8484
Nov 4, 2024 8.9984 0.1100 1.24% 8.8884 9.3484 7.8584

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Corvus Pharmaceuticals, Inc. Company profile

About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which is engaged in the development and commercialization of precisely targeted oncology therapies. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression; and CPI-935, Adenosine A2B Receptor Antagonist.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Corvus Pharmaceuticals Inc revenues was not reported. Net loss increased from $6M to $43.2M. Higher net loss reflects Gain on deconsolidation of Angel Pharmac decrease from $37.5M (income) to $0K, Loss from equity method investment increase from $234K to $4.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.20 to -$1.03.

Industry: Biotechnology & Medical Research (NEC)

863 Mitten Rd Ste 102
BURLINGAME
CALIFORNIA 94010-1311
US

News

Silver coins and bullion

Silver price forecast: Third party price target

Rising interest rates and a strong dollar pushed silver to a two-year last September, but what lies ahead?

16:00, 3 December 2024
SHIB cryptocurrency logo, showing a cartoon Shiba Inu dog on a coin, over a golden orange background with circuit board graphics detail

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

16:41, 28 November 2024
Gold bars on a black background with a diagram

Gold price predictions for the next five years: Third party data round up

Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.

15:17, 18 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

FOMC and BOE preview: further rate cuts expected

Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.

14:14, 5 November 2024

People also watch

BTC/USD

95,039.20 Price
-0.390% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

XRP/USD

2.50 Price
-7.550% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01246

Oil - Crude

69.90 Price
+2.690% 1D Chg, %
Long position overnight fee 0.0036%
Short position overnight fee -0.0255%
Overnight fee time 22:00 (UTC)
Spread 0.030

ETH/USD

3,553.39 Price
-1.740% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading